Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to aflibercept in neovascular AMD non-responders
2013-001208-12Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Radboud University Medical Center. Primary endpoint: Change in central retinal thickness. Started May 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-001208-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001208-12.